Alcon (ALC) said Monday it is planning to acquire Lensar (LNSR) for a total consideration of about $430 million.
Under the terms of the deal, Alcon will purchase all outstanding shares of Lensar for $14 per share in cash, with an additional non-tradeable contingent value right offering up to $2.75 per share in cash, conditioned on the achievement of 614,000 cumulative procedures with Lensar's products between Jan. 1, 2026, and Dec. 31, 2027.
The acquisition includes the Ally Robotic Cataract Laser Treatment System, Streamline software technology, and Lensar's legacy laser system.
The transaction is expected to close in mid-to-late 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。